Since its, discovery three decades ago, sterol carrier protein-2 (SCP-2) ha
s remained a fascinating protein whose physiological function in lipid meta
bolism remains an enigma. Its multiple proposed functions arise from its, c
omplex gene structure, post-translational processing, intracellular localiz
ation, and ligand specificity. The SCP-2 gene has two initiation sites codi
ng for proteins that share a common 13 kDa SCP2 C-terminus: (1) One site co
des for 58 kDa SCP-x which is partially post-translationally cleaved to 13
kDa, SCP-2 and a 45 kDa protein. (2) A second site codes for 15 kDa pro-SCP
-2 which is completely posttranslationally cleaved to 13 kDa SCP-2. Very ti
ttle is yet known regarding how the relative proportions of the two transcr
ipts are regulated. Although all three proteins contain a C-terminal SKL pe
roxisomal targeting sequence, it is unclear why all three proteins are not
exclusively localized in peroxisomes. However, the recent demonstration tha
t the SCP-2 N-terminal presequence in pro-SCP-2 dramatically modulated the
intracellular targeting coded by the C-terminal peroxisomal targeting seque
nce may account for the observation that as, much as half of total SCP-2 is
localized outside the peroxisome. The tertiary and secondary structure of
the 13 kDa SCR-2, but not that of 15 kDa pro-SCP-2 and 58 kDa SCP-x, are no
w resolved. Increasing evidence suggests that the 58 kDa SCP-x and 45 kDa p
roteins are peroxisomal 3-ketoacyl-CoA-thiolases involved in the oxidation
of branched chain fatty acids. Since 15 kDa pro-SCP-2 is post-translational
ly completely cleaved to 13 kDa SCP-2, relatively little attention has been
focused on this protein. Finally, although the 13 kDa SCP-2 is the most st
udied of these proteins, because it exhibits diversity of its ligand partne
rs (fatty acids, fatty acyl CoAs, cholesterol, phospholipids), new potentia
l physiological function(s) are still being proposed and questions regardin
g potential compensation by other proteins with overlapping specificity are
only beginning to be resolved. (C) 2001 Elsevier Science Ltd. All rights-r
eserved.